Company: CDT
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001641172-25-024140
Chunk: 150

Company: CDT Equity Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 2
Chunk 150
---
 sector.

Through
this relationship, CDT will gain access to cutting-edge predictive models and dashboards, enabling the Company to evaluate drug candidates,
streamline clinical trials, and optimize asset management with real-time data. These tools will drive faster, more accurate decisions,
improving efficiency and reducing costs. By leveraging these insights, CDT can differentiate itself in a competitive sector and gain unique
data-driven insights that position the Company for success across both its current and future asset portfolio.

A further
partnership with Manoira enables CDT Equity to expand the scope of its drug portfolio into the animal health market in a cost-efficient
manner. This collaboration allows us to accelerate the understanding of the mechanism of action, safety, and potential efficacy of its
portfolio across multiple species, while retaining 100% ownership of all data and intellectual property generated relating for human applications.
This is expected to enhance the core human therapeutic pipeline but also opens potential new revenue streams in the high-growth veterinary
market.

Repositioning
CDT Equity enables the company to explore multiple opportunities in the healthcare, biotech and broader technology innovation. The Board
continue to evaluate a cryptocurrency treasury reserve strategy, working with consultants to best advise a novel market which has seen
significant recent activity and success for respective stakeholders. Long-term exposure to digital assets can present both strategic and
financial benefits as part of a diversified capital management approach.

Operating with a lean, disease-agnostic
model, CDT Equity prioritizes speed, adaptability, and capital efficiency. We avoid the cost burden of late-stage clinical trials, focusing
instead on high-leverage development strategies. Led by highly experienced executives: Dr. Freda Lewis-Hall, former Chief Medical Officer
of Pfizer Inc., the Chair of the Board; Dr. Andrew Regan, CEO and James Bligh, CFO. Our management team includes active senior scientists
who have an extensive understanding of the pharmaceuticals market, supporting our strategy of developing clinical assets in a cost-efficient
manner focused on therapeutic efficacy.

In 2024, AstraZeneca granted a
license to the Company under certain intellectual property rights controlled by AstraZeneca related to HK-4 Glucokinase activators AZD1656
and AZD5658 in all indications and myeloperoxidase inhibitor AZD5904 for the treatment, prevention, and prophylaxis of idiopathic male
infertility. The Company will be responsible for development and commercialization of the Licensed Products under the related License
Ag